The NHS in England has approved fampridine, a multiple sclerosis drug that restores mobility in patients whose walking ability deteriorated from the disease. The medication works by boosting nerve signals in the spinal cord, making movement easier and faster for eligible patients.
Fampridine, sold under the brand name Ampyra, addresses a core symptom affecting MS patients. The drug improves conduction of electrical impulses along damaged nerve fibers, effectively compensating for myelin loss. Clinical trials showed patients could walk faster and with greater confidence after treatment began.
Up to 5,000 people with MS in England qualify for the drug under NHS coverage. Eligibility criteria target those whose walking ability deteriorated from progressive or relapsing-remitting MS. The approval reflects growing recognition that mobility restoration offers substantial quality-of-life improvements beyond symptom management alone.
Patient advocates have described fampridine as life-changing. Users report regained independence, reduced reliance on mobility aids, and renewed ability to perform daily activities. For many, improved walking capacity translates to employment prospects and social participation previously lost to disease progression.
The NHS decision follows years of campaigning by patient groups and clinicians who argued the drug's benefits justified its cost. Fampridine represents a shift in MS treatment philosophy, moving beyond anti-inflammatory approaches toward functional restoration. The drug complements existing disease-modifying therapies rather than replacing them.
Rollout will occur through specialist MS centers across England. Neurologists will assess candidates using standardized walking tests to confirm fampridine's potential benefit before prescription. The approval expands treatment options for MS populations often frustrated by medications addressing inflammation while leaving mobility severely compromised.